The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 12.469
Citescore: 14.3
All metrics >>
Highlighted Articles
COVID-19 and Cancer Immunotherapy
Latest Articles
Clinical/translational cancer immunotherapy:
Blocking soluble TNF{alpha} sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression8 March 2023
Clinical/translational cancer immunotherapy:
Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity8 March 2023
Clinical/translational cancer immunotherapy:
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy8 March 2023
Correction:
Correction: Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells8 March 2023
Basic tumor immunology:
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-{alpha} triggers tumorigenic inflammation in neuroblastoma7 March 2023
Most Read Articles
Immunotherapy biomarkers:
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment21 July 2022
Review:
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells17 May 2022
Review:
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy4 April 2022
Position article and guidelines:
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)29 September 2022
Altmetrics
What Our Editors Are Reading
In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
Explore SITC’s cancer immunotherapy community at sitcancer.org and become a member to take advantage of SITC’s member benefit of 50% off APCs for all articles submitted and accepted in JITC in 2022.